Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3

Cellular and Molecular Life Sciences

Volumn 70, Issue 20, 2013, Pages 3973-3985

  Nilvebrant, Johan ^a   Åstrand, Mikael ^a   Löfblom, John ^a   Hober, Sophia ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

ABD; Albumin binding domain; Bispecific; ErbB3; HSA; Phage display

Indexed keywords

ALBUMIN; BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR; PROTEIN VARIANT;

ALBUMIN BINDING DOMAIN; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PHAGE DISPLAY; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; THERMOSTABILITY;

BACTERIAL PROTEINS; BINDING, COMPETITIVE; BIOSENSING TECHNIQUES; ESCHERICHIA COLI; HUMANS; LIGANDS; NERVE GROWTH FACTORS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ERBB-3; SERUM ALBUMIN; TEMPERATURE;

EID: 84884908517     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1370-9     Document Type: Article

References (54)

1. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327. doi: 10.1038/nri2744
2. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278-287. doi: 10.1038/nrc3236
3. Lofblom J, Frejd FY, Stahl S (2011) Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol 22(6):843-848. doi: 10.1016/j.copbio.2011.06.002
4. Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13(3):245-255. doi: 10.1016/j.cbpa.2009.04.627
5. Gilbreth RN, Koide S (2012) Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr Opin Struct Biol 22(4):413-420. doi: 10.1016/j.sbi.2012.06.001
6. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, Pluckthun A (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 70(4):1595-1605. doi: 10.1158/0008-5472.CAN-09-2724
7. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8(10):2861-2871. doi: 10.1158/1535-7163.MCT-09-0195
8. Kontermann RE (2009) Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 23(2):93-109. doi: 10.2165/00063030-200923020- 00003
9. Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Control Release 161(2):429-445. doi: 10.1016/j.jconrel.2011.11.028
10. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S (2006) Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 27(7):343-348. doi: 10.1016/j.it.2006.05.004
11. Stork R, Campigna E, Robert B, Muller D, Kontermann RE (2009) Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 284(38):25612-25619. doi: 10.1074/jbc.M109.027078
12. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Muller D, Kontermann RE (2010) The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 23(11):827-834. doi: 10.1093/protein/gzq058
13. Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kontermann RE (2012) Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem 287(7):4462-4469. doi: 10.1074/jbc.M111.311522
14. Unverdorben F, Färber-Schwarz A, Richter F, Hutt M, Kontermann RE (2012) Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal Protein A. Protein Eng Des Sel 25(2):81-88. doi: 10.1093/protein/gzr061
15. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, Williams S, Cole MJ, Ross S, Schwall R (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67(1):254-261. doi: 10.1158/0008-5472.CAN-06-2531
16. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandstrom M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY (2007) Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67(6):2773-2782. doi: 10.1158/0008-5472.CAN-06-1630
17. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen L, Ekblad C (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin-binding domain. J Biol Chem 286(7):5234-5241. doi: 10.1074/jbc.M110.164848
18. Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H (1998) Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 76(6):884-890. doi: 10.1002/(sici)1097- 0215(19980610)76:6<884:aid-ijc19>3.0.co;2-2
19. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, Heene DL (1997) Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26(2):77-100
20. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48(10):2641-2658
21. Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH (2001) Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 92(5):718-724
22. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25(12):1411-1419. doi: 10.1038/nbt1364
23. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 102(4):634-644. doi: 10.1160/TH09-04-0255
24. Flisiak R, Flisiak I (2010) Albinterferon-alpha 2b: a new treatment option for hepatitis C. Expert Opin Biol Ther 10(10):1509-1515. doi: 10.1517/14712598.2010.521494
25. Alm T, Yderland L, Nilvebrant J, Halldin A, Hober S (2010) A small bispecific protein selected for orthogonal affinity purification. Biotechnol J 5(6):605-617. doi: 10.1002/biot.201000041
26. Nilvebrant J, Alm T, Hober S, Lofblom J (2011) Engineering bispecificity into a single albumin-binding domain. PLoS ONE 6(10):e25791. doi: 10.1371/journal.pone.0025791
27. Makrides SC, Nygren PA, Andrews B, Ford PJ, Evans KS, Hayman EG, Adari H, Uhlen M, Toth CA (1996) Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 277(1):534-542
28. Ahmad JN, Li J, Biedermannova L, Kuchar M, Sipova H, Semeradtova A, Cerny J, Petrokova H, Mikulecky P, Polinek J, Stanek O, Vondrasek J, Homola J, Maly J, Osicka R, Sebo P, Maly P (2012) Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of Protein G. Proteins 80(3):774-789. doi: 10.1002/prot.23234
29. Linhult M, Binz HK, Uhlen M, Hober S (2002) Mutational analysis of the interaction between albumin-binding domain from streptococcal Protein G and human serum albumin. Protein Sci 11(2):206-213. doi: 10.1110/ps.02802
30. Kraulis PJ, Jonasson P, Nygren PA, Uhlen M, Jendeberg L, Nilsson B, Kordel J (1996) The serum albumin-binding domain of streptococcal Protein G is a three-helical bundle: a heteronuclear NMR study. FEBS Lett 378(2):190-194
31. Cramer JF, Nordberg PA, Hajdu J, Lejon S (2007) Crystal structure of a bacterial albumin-binding domain at 1.4 A resolution. FEBS Lett 581(17):3178-3182. doi: 10.1016/j.febslet.2007.06.003
32. Citri A, Skaria KB, Yarden Y (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284(1):54-65
33. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137. doi: 10.1038/35052073
34. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463-475. doi: 10.1038/nrc2656
35. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3 K axis. Sci Signal 2 (77): ra31 doi: 10.1126/scisignal.2000352
36. Carlsson J (2012) Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumor Biol 33(3):653-659. doi: 10.1007/s13277-011-0307-x
37. Linggi B, Carpenter G (2006) ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem 281(35):25373-25380. doi: 10.1074/jbc.M603998200
38. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70(3):1204-1214. doi: 10.1158/0008-5472.CAN-09-3321
39. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126):437-441. doi: 10.1038/nature05474
40. Foreman PK, Gore M, Kobel PA, Xu L, Yee H, Hannum C, Ho H, Wang SM, Tran HV, Horowitz M, Horowitz L, Bhatt RR (2012) ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther 11(7):1411-1420. doi: 10.1158/1535-7163.MCT-12-0068
41. Grovdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B (2012) EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 24(1):296-301. doi: 10.1016/j.cellsig.2011.09.012
42. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sanchez V, Koland J, Muller WJ, Arteaga CL, Cook RS (2012) HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72(10):2672-2682. doi: 10.1158/0008-5472.CAN-11-3594
43. Amin DN, Sergina N, Lim L, Goga A, Moasser MM (2012) HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 447(3):417-425. doi: 10.1042/BJ20120724
44. Ruther U (1982) pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts. Nucleic Acids Res 10(19):5765-5772
45. Kronqvist N, Malm M, Gostring L, Gunneriusson E, Nilsson M, Hoiden Guthenberg I, Gedda L, Frejd FY, Stahl S, Lofblom J (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific affibody molecules. Protein Eng Des Sel 24(4):385-396. doi: 10.1093/protein/gzq118
46. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E, Henrichson C, Jones TA, Uhlen M (1987) A synthetic IgG-binding domain based on staphylococcal Protein A. Protein Eng 1(2):107-113
47. Johansson MU, Frick IM, Nilsson H, Kraulis PJ, Hober S, Jonasson P, Linhult M, Nygren PA, Uhlen M, Bjorck L, Drakenberg T, Forsen S, Wikstrom M (2002) Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 277(10):8114-8120. doi: 10.1074/jbc.M109943200
48. Gulich S, Linhult M, Nygren P, Uhlen M, Hober S (2000) Stability towards alkaline conditions can be engineered into a protein ligand. J Biotechnol 80(2):169-178
49. Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161(6):1219-1237. doi: 10.1111/j.1476-5381.2009.00604.x
50. Hosse RJ, Rothe A, Power BE (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15(1):14-27. doi: 10.1110/ps.051817606
51. Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, Lofblom J, Gedda L (2012) Cellular effects of HER3-specific affibody molecules. PLoS ONE 7(6):e40023. doi: 10.1371/journal.pone.0040023
52. Lejon S, Frick IM, Bjorck L, Wikstrom M, Svensson S (2004) Crystal structure and biological implications of a bacterial albumin-binding module in complex with human serum albumin. J Biol Chem 279(41):42924-42928. doi: 10.1074/jbc.M406957200
53. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM (2008) Anti-serum albumin domain antibodies for extending the half-lives of short-lived drugs. Protein Eng Des Sel 21(5):283-288. doi: 10.1093/protein/ gzm067
54. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277(38):35035-35043. doi: 10.1074/jbc.M205854200